Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Harvard BioscienceHBIO 53 Debt-to-EBITDA is -33.82 as of Jun. 2026. GuruFocus rates HBIO with a GF Score™ of 53/100 and a GF Value™ of $12.30 (Possible Value Trap). The stock has 9 warning signs investors should review. Among 471 Medical Devices & Instruments companies, Harvard Bioscience ranks worse than 99.79% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Harvard Bioscience's Debt-to-EBITDA or its related term are showing as below:
HBIO'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -45.78 Med: 6.9 Max: 61.94
Current: 61.94
During the past 13 years, the highest Debt-to-EBITDA Ratio of Harvard Bioscience was 61.94. The lowest was -45.78. And the median was 6.90.
HBIO's Debt-to-EBITDA is ranked worse than 99.79% of 471
companies
in the Medical Devices & Instruments industry
Industry Median: 1.63
vs HBIO: 61.94
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Harvard Bioscience Debt-to-EBITDA Related Terms
Harvard Bioscience Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Harvard Bioscience's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HBIO vs MLSS, FEMY, POCI: Debt-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Harvard Bioscience's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Harvard Bioscience Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Harvard Bioscience's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Harvard Bioscience's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Harvard Bioscience (HBIO) has a Debt-to-EBITDA of -33.82 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Harvard Bioscience. According to the industry distribution chart, Harvard Bioscience ranks #470 out of 471 companies in the Medical Devices & Instruments industry, placing it in the top 99.8%.
Is Harvard Bioscience's Debt-to-EBITDA too high?
Harvard Bioscience's current Debt-to-EBITDA is -33.82. Based on the distribution chart, Harvard Bioscience ranks #470 out of 471 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Harvard Bioscience has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Harvard Bioscience's Debt-to-EBITDA compare to MLSS and FEMY?
According to the Medical Devices & Instruments industry distribution chart, Harvard Bioscience ranks #470 out of 471 companies for Debt-to-EBITDA. This places Harvard Bioscience in the lower half of its industry. The industry median Debt-to-EBITDA is 1.63. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.63, based on 471 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Harvard Bioscience. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Harvard Bioscience's current Debt-to-EBITDA is -33.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harvard Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Harvard Bioscience (HBIO) is currently considered Possible Value Trap. The stock's GF Value™ is $12.30, compared to a current price of $8.06 — trading 34.5% below its estimated fair value. The current Debt-to-EBITDA is -33.82. Harvard Bioscience's overall GF Score™ is 53/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Harvard Bioscience (HBIO), the current Debt-to-EBITDA is -33.82 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Harvard Bioscience (HBIO) Overvalued in 2026?
Based on GuruFocus' analysis, Harvard Bioscience stock appears to be undervalued.
The current stock price of $8.06 is trading 34.5% below its estimated GF Value™ of $12.30.
GuruFocus considers Harvard Bioscience to be Possible Value Trap.
Key valuation signals for HBIO:
Debt-to-EBITDA: -33.82
GF Value™: $12.30 vs. price of $8.06 (34.5% below fair value)
No single metric tells the full story. See the HBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.
53GF Score
Get the complete analysis for HBIO
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HBIO has been successfully added to your 
